BioLineRx Ltd.
A clinical-stage biopharmaceutical company developing therapies for oncology and rare diseases.
BLRX | TA
Overview
Corporate Details
- ISIN(s):
- US09071M2052 (+1 more)
- LEI:
- 529900AKIOSC15Y63R18
- Country:
- Israel
- Address:
- Modi'in Technology Park, 2 HaMa'ayan Street, 7177871 Modi'in
- Website:
- https://www.biolinerx.com/
- Sector:
- Manufacturing
Description
BioLineRx Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for oncology and rare diseases. The company leverages its drug development capabilities to advance novel, early-stage therapeutic candidates through the clinical development process toward regulatory approval. Its pipeline consists of treatments, including small molecules, designed to address unmet medical needs and deliver meaningful benefits to patients. BioLineRx also partners with other drug developers to advance their early-stage programs.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-03-28 11:12 |
Form 20-F/A (Amendment No. 1
|
English | 1.2 MB | ||
| 2024-03-28 11:12 |
Form 20-F/A (Amendment No. 1
|
English | 39.4 KB | ||
| 2024-03-26 15:30 |
Annual Report on Form 20-F FOR 2023
|
English | 1.4 MB | ||
| 2024-03-26 15:30 |
Annual Report on Form 20-F FOR 2023
|
English | 36.4 KB | ||
| 2024-03-26 15:21 |
Annual Report on Form 20-F
|
English | 165.1 KB | ||
| 2024-03-26 15:21 |
Annual Report on Form 20-F
|
English | 36.4 KB | ||
| 2024-03-26 14:27 |
Reports 2023 Financial Results and Recent Corporate and Portfolio Updates
|
English | 165.1 KB | ||
| 2024-03-26 14:27 |
Reports 2023 Financial Results and Recent Corporate and Portfolio Updates
|
English | 36.4 KB | ||
| 2024-03-04 15:05 |
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for…
|
English | 219.7 KB | ||
| 2024-03-04 15:05 |
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for…
|
English | 36.5 KB | ||
| 2024-02-28 15:05 |
BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clini…
|
English | 223.1 KB | ||
| 2024-02-28 15:05 |
BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clini…
|
English | 36.5 KB | ||
| 2024-02-18 12:06 |
BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixaf…
|
English | 246.9 KB | ||
| 2024-02-18 12:06 |
BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixaf…
|
English | 36.5 KB | ||
| 2023-12-31 10:44 |
FORM F-3-REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
|
English | 429.7 KB |
Automate Your Workflow. Get a real-time feed of all BioLineRx Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BioLineRx Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BioLineRx Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
